MedTrace Logo

Impact of Hepatitis C Therapy and Bone Health

NCT03221582 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-08-19

No results posted yet for this study

Summary

An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.

Conditions

  • Human Immunodeficiency Virus
  • Hepatitis C

Interventions

DRUG

EBR/GZR

Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.

Sponsors & Collaborators

Principal Investigators

  • Roger Bedimo, MD · Dallas VAMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-28
Primary Completion
2018-11-26
Completion
2018-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03221582 on ClinicalTrials.gov